Clinical trials: Neuron Disease, Motor
ALS
A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients
The purpose of this study is to investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TCD601 (siplizumab) in newly diagnosed adult ALS patients.
- Trial name
- AURORA (NCT06453668)
- Testing
- TCD601
- Where
- 3 sites in Sweden
- Volunteers
- 7 people
- Sponsor
- ITB-Med LLC
Amyotrophic Lateral Sclerosis (ALS)
Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults
The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of FHND1002 granules in healthy adult volunteers.
- Trial name
- FHND1002-Ⅰ (NCT06782958)
- Testing
- 50mg FHND1002, 100mg FHND1002, 150 mg FHND1002
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Amyotrophic Lateral Sclerosis
Accurate Test of Limb Isometric Strength (ATLIS) in ALS
A strength measurement device called Accurate Test of Limb Isometric Strength (ATLIS) was developed to precisely and conveniently measure static limb strength in patients with ALS.
- Trial name
- NCT02374606
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cedars-Sinai Medical Center
Amyotrophic Lateral Sclerosis
The Effect of Intensive Controlled Exercise in the Early Stages of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurological disorder characterized by amongst others asymmetric muscle weakness, respiratory insufficiency and spasticity.
- Trial name
- NCT00160004
- Testing
- Intensive Controlled Exercise
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Motor Neuron Disease
Technical Evaluation of Earswitch Phase B
The Earswitch is a demonstrated proof-of-concept that detects the voluntary contraction of a small muscle in the ear, called the tensor tympani (TT) muscle, which can be effectively used as an input switch.
- Trial name
- NCT06090448
- Testing
- EarSwitch device
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Bath
Amyotrophic Lateral Sclerosis
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this research study is to evaluate the safety and effectiveness of CK-2017357 when taken with or without riluzole (also called Rilutek®) in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01709149
- Testing
- CK-2017357, Riluzole
- Where
- 75 sites in United States, Canada and 6 more
- Volunteers
- 711 people
- Sponsor
- Cytokinetics
Amyotrophic Lateral Sclerosis (ALS)
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This is a Phase 3, international, multicenter, open-label, long-term extension study. The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral…
- Trial name
- NCT04577404
- Testing
- MT-1186
- Where
- 44 sites in United States, Canada and 4 more
- Volunteers
- 124 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis
Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells
Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation. The major goal of the project is to develop human iPS cells from various types of cell cultures or lines…
- Trial name
- NCT00801333
- Where
- 2 sites in Israel
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Muscular Atrophy, Spinal
A Real-World Study of Clinical Use of Available Treatments for Pediatric Patients With Spinal Muscular Atrophy
The aim of this study was to evaluate real-world treatment patterns and clinical outcomes in pediatric SMA patients in the Czech and Slovak Republics, using data from the Registry of muscular Dystrophy (REaDY).
- Trial name
- NCT07474311
- Where
- Czechia
- Volunteers
- 213 people
- Sponsor
- Novartis Pharmaceuticals
Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
The ONYX study is an Open-Label, Multicenter, Extension study that will evaluate the long-term safety and efficacy of Apitegromab in Patients with Type 2 and Type 3 SMA who have completed TOPAZ or SAPPHIRE.
- Conditions
- Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA
- Trial name
- ONYX (NCT05626855)
- Testing
- Apitegromab
- Where
- 49 sites in United States, Belgium and 7 more
- Volunteers
- 238 people
- Sponsor
- Scholar Rock, Inc.
Primary Lateral Sclerosis
Screening and Natural History: Primary Lateral Sclerosis and Related Disorders
Objective: The objectives of this protocol are: to develop and maintain a repository of clinically characterized patients with primary lateral sclerosis for future research protocols, to characterize the natural history of…
- Trial name
- NCT00015444
- Where
- United States
- Volunteers
- 189 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the safety of HLA-haplo matched Allogenic Bone Marrow Derived stem cells("HYNR-CS-Allo inj"), through intrathecal delivery for the treatment in patients with amyotrophic lateral…
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Disease, Neurodegenerative Disease
- Trial name
- NCT01758510
- Testing
- HYNR-CS-Allo
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Hanyang University Seoul Hospital
Amyotrophic Lateral Sclerosis
Salivary Biomarker Discovery by Raman Spectroscopy in ALS (SalivALS)
BACKGROUND/RATIONALE: The paucity of biomarkers for the diagnosis and monitoring of patients affected by Amyotrophic Lateral Sclerosis (ALS) is one of the greatest concerns in ALS clinics and research.
- Trial name
- SalivALS (NCT04233099)
- Testing
- Raman analysis of saliva with data collection and analysis
- Where
- 2 sites in Italy
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Amyotrophic Lateral Sclerosis (ALS)
Extension Study of Participants From SPG302-ALS-001
This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALS-101 with Amyotrophic Lateral Sclerosis (ALS)
- Trial name
- NCT06903286
- Testing
- SPG302
- Where
- 3 sites in Australia
- Volunteers
- 16 people
- Sponsor
- Spinogenix
ALS (Amyotrophic Lateral Sclerosis)
Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease which involves respiratory muscles and can lead at short term to respiratory failure.
- Trial name
- SLA (NCT02528071)
- Testing
- Diaphragmatic endurance test
- Where
- France
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Amyotrophic Lateral Sclerosis
Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls
The purpose of this study is to study the transporters of serotonin and dopamine in ALS patients in relation with the clinical phenotype, i.e., patients without stiffness, patients with pyramidal stiffness, patients with mixed…
- Trial name
- DOSERAL (NCT01160263)
- Testing
- SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
- Where
- 2 sites in France
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Amyotrophic Lateral Sclerosis
Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS)
The objective of this phase III, placebo-controlled platform study is to investigate the efficacy of drugs for patients with ALS (Amyotrophic lateral sclerosis).
- Trial name
- NCT06008249
- Testing
- Lithium Carbonate 400 MG
- Where
- 13 sites in Australia, Belgium and 4 more
- Volunteers
- 88 people
- Sponsor
- Stichting TRICALS Foundation
Amyotrophic Lateral Sclerosis
CuATSM Compared With Placebo for Treatment of ALS/MND
Multicenter, randomized, double-blind, placebo controlled study to assess the tolerabilty and efficacy of CuATSM in patients with ALS/MND.
- Trial name
- NCT04082832
- Testing
- Cu(II)ATSM
- Where
- Australia
- Volunteers
- 80 people
- Sponsor
- Collaborative Medicinal Development Pty Limited
ALS (Amyotrophic Lateral Sclerosis)
Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the safety of Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis by a prospective, single-center, randomized, parallel…
- Trial name
- TCIM/ELA (NCT02286011)
- Testing
- MNC (Mononuclear cells), Saline
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Red de Terapia Celular
ALS (Amyotrophic Lateral Sclerosis)
T-regulatory Cells in ALS
This study is a randomized, placebo-controlled, phase 2a trial to study the biological activity, safety, and tolerability of regulatory T Lymphocytes (Tregs) taken and expanded outside of the body and returned back to the same…
- Trial name
- Tregs in ALS (NCT04055623)
- Testing
- Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- The Methodist Hospital Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.